Rhumbline Advisers Actinium Pharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 38,996 shares of ATNM stock, worth $47,575. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,996
Previous 39,656
1.66%
Holding current value
$47,575
Previous $293,000
75.09%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ATNM
# of Institutions
74Shares Held
8.31MCall Options Held
65.2KPut Options Held
21.7K-
Black Rock Inc. New York, NY1.88MShares$2.29 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$1.98 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA686KShares$837,1060.0% of portfolio
-
State Street Corp Boston, MA603KShares$735,2310.0% of portfolio
-
Acadian Asset Management LLC Boston, MA454KShares$553,5060.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $30.7M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...